L'asthme est l'une des affections courantes les plus maîtrisables, et le traitement qui le maîtrise est le corticoïde inhalé qui apaise les voies respiratoires. L'inhalateur bleu de secours sur lequel la plupart des gens s'appuient soulage une crise sur le moment, mais laisse l'inflammation sous-jacente sans traitement.
Le tableau a évolué ces dernières années. Un corticoïde à faible dose associé à un bronchodilatateur à action rapide, pris lorsque les symptômes s'aggravent, prévient désormais les crises graves bien mieux qu'un inhalateur de secours utilisé seul.
Practice Ranking
Every practice we track for Asthma: getting it under control, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
5 practices · 2 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Quitting Smoking: What It Does to the Body and the Methods That Actually Work Improves lung function and control; the single biggest change for a smoker. | Strong | Pro | Free to $$ | Hard | Days to Longer | |
| 2 | Breathwork and HRV: The Research, the Practice, and How to Start Breathing retraining eases day-to-day symptoms and quality of life, though it does not change how your lungs test. | Moderate | Self-Directed | Free | Easy | Days to Weeks | |
| 3 | Zone 2 Cardio: What the Training Does, and Where the Claims Run Ahead of the Evidence Regular aerobic training builds fitness and is safe in asthma that is reasonably controlled. | Moderate | Self-Directed | Free to $$ | Moderate | Weeks to Months | |
| 4 | Weight Loss: The Single Strongest Lever for Metabolic Health, and What the Trials Actually Show Improves control in people with obesity. | Moderate | Self-Directed | Free to $$$ | Moderate to Hard | Weeks to Months | |
| 5 | Vitamin D No overall effect on attacks; worth correcting only a genuine deficiency. | Emerging | Supplement | $ | Easy | Weeks to Months | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Asthma is an inflamed, over-reactive airway. When a trigger sets it off, the airway narrows, swells, and fills with mucus, and that is the wheeze, cough, chest tightness, and breathlessness. Cold air, an allergen, a cold virus, exercise, or smoke can each tip a sensitive airway into a flare.
The inflammation is the disease; the narrowing is the symptom. Different inhalers treat the two, and only the one that treats the inflammation alters its course.
Asthma comes in a few recognizable patterns:
- Allergic (eosinophilic) asthma is the most common. An allergic type of inflammation drives it, it often runs alongside hay fever and eczema, it frequently starts in childhood, and it responds best to inhaled steroids.
- Non-allergic asthma more often begins in adulthood, is sometimes linked to weight or aspirin sensitivity, and can be less steroid-responsive.
- Exercise-induced bronchoconstriction is wheeze during or shortly after exertion, especially in cold, dry air, a reason to control the asthma.
- Severe asthma keeps flaring despite high-dose inhaled steroids taken correctly, often with a high eosinophil count. Modern biologic drugs were built for this group.
Asthma, hay fever, and eczema tend to occur together as one allergic tendency, so an uncontrolled nose can worsen the chest below it.
What controls it
The controller keeps you well, so take it every day and do not stop when symptoms settle down.
A daily inhaled corticosteroid, the controller, calms the airway inflammation that drives asthma, and it is the treatment that changes the disease. In the START trial of 7,241 people with recent, mild asthma, a low daily dose nearly halved the risk of a severe attack over three years (hazard ratio 0.56). The blue reliever does the opposite job. It opens the airway for a few hours and leaves the inflammation untouched.
The larger shift of recent years is in what you reach for when symptoms flare. A low-dose steroid combined with fast-acting formoterol, taken only as needed, guards against severe attacks much more than a plain blue reliever used alone. It cut severe attacks to about a third of the reliever-alone rate in the SYGMA 1 trial. The real-world Novel START trial put the reduction at about half, and both used far less steroid than a daily controller. This is a change to make with your prescriber.
How quickly you use up the reliever is itself a measure of how well the asthma is controlled. In the SABINA cohort of 365,324 people, those going through more than two reliever canisters a year had steadily more attacks and a higher risk of dying. The risk climbed with each extra canister, reaching up to 77% more attacks in people collecting 11 or more a year. People who get through a lot of reliever often have worse asthma to begin with, so this does not prove the reliever itself causes the harm. A canister running down fast is a reliable prompt to have the treatment reviewed.
Then come the levers that support the core treatment and never replace it:
- Inhaler technique and not smoking. Much of the disappointment with inhalers comes down to how they are used, so a few minutes having your technique checked makes a large difference. Smoking counts just as much. In a crossover trial, non-smokers with asthma improved clearly on a course of steroid tablets, with FEV1 up 237 mL. Active smokers got no benefit on any measure, and ex-smokers responded partway. Smoking blunts the very treatment that controls asthma, and stopping restores some of the response.
- Losing weight, if you carry extra. This is the free, self-directed lever, and its effect is large. In a randomized trial, a loss of 5 to 10% of body weight improved asthma control in 58% of overweight and obese adults, and quality of life in 83%. Much adult, weight-linked asthma tracks the ultra-processed diet built around fat, sugar, and salt, so changing what you eat targets the share of asthma that extra weight drives.
- Staying active. Across 21 trials, regular training raised fitness by 4.92 mL/kg/min of oxygen uptake, improved quality of life, and was well tolerated. It did not worsen asthma. If exercise reliably brings on symptoms, that points to asthma that needs tighter control.
- Breathing retraining. In a Cochrane review of 22 trials and the 655-adult BREATHE trial, breathing retraining improved asthma quality of life by 0.42 points on the AQLQ. On that 1–7 scale, about 0.5 is the smallest change patients notice. Lung function and airway inflammation barely changed. It eases symptoms and helps you cope.
Two treatments are aimed at specific groups:
- Allergen immunotherapy, where a confirmed allergy clearly drives the asthma, lowered symptoms and the medication people needed across 88 trials. Injection immunotherapy carries a small but real risk of a serious allergic reaction. About one in nine people have a whole-body allergic reaction, so it is given somewhere staff can treat one if it happens.
- A biologic, for severe asthma that keeps flaring despite correctly used high-dose inhaled steroids, roughly halves attacks in the subgroup whose inflammation is eosinophilic. In the MENSA trial, mepolizumab cut exacerbations by about half, 47 to 53%, in people identified by a high blood eosinophil count. Biologics are specialist treatments layered on top of inhaled steroids, confirmed with blood tests first.
To recover from a bad attack, a short course of steroid tablets cut the chance of relapsing in the first week (relative risk 0.38). It also reduced return hospital visits, with no clear rise in side effects. It is a short rescue course, started early and then stopped.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Respiratory
A daily inhaled steroid nearly halved severe attacks over three years
A low daily dose of an inhaled steroid nearly halved the chance of a severe asthma attack over three years, compared with a dummy inhaler, in people with early, mild asthma. It works by calming the airway over time, so it is taken every day whether or not you feel symptoms.
In the START trial, 7,241 people aged 5 to 66 with mild persistent asthma of recent onset were randomized to once-daily low-dose inhaled budesonide or placebo for 3 years on top of usual medication. The time to a first severe asthma-related event was longer on budesonide: 117 of 3,597 on budesonide versus 198 of 3,568 on placebo had at least one severe exacerbation, a hazard ratio of 0.56 (95% CI 0.45 to 0.71). The steroid group also needed fewer courses of oral steroids and had more symptom-free days. Measured in: 7,241 people aged 5 to 66 with mild persistent asthma of less than two years' duration, not previously on regular steroids, in a randomized double-blind trial across 32 countries. This was a mild, recent-onset population, so the size of the benefit will differ in longer-standing or more severe asthma, and the low-dose inhaled steroid slightly reduced three-year growth in the youngest children (by about 0.5 inches (1.3 cm)). It calms inflammation over time, not opening the airway on the spot, so it is taken every day, not for symptoms.
Who this may not transfer to:Both sexes were enrolled across children and adults; the trial does not report the exacerbation effect separately by sex.
Treat the controller inhaler as the core of asthma treatment and take it daily, not only when symptoms flare. The benefit builds with regular use and fades if it is stopped.
The study · 1
Pauwels et al., early intervention with budesonide in mild persistent asthma (the START trial), a randomised double-blind trial · Lancet 2003;361(9363):1071-1076
An as-needed steroid-formoterol reliever cut severe attacks to about a third of a blue reliever's rate
Taking a combined steroid-and-opener inhaler only when symptoms flared cut severe attacks to about a third of the rate seen with a plain blue reliever used the same way, and used far less steroid than a daily controller. This is the modern move away from reaching for a blue inhaler alone.
In the SYGMA 1 trial, 3,849 people aged 12 and over with mild asthma were randomized to an as-needed inhaled steroid-plus-formoterol combination, an as-needed short-acting reliever (terbutaline) alone, or maintenance budesonide plus reliever. The annual rate of severe exacerbations was 0.07 with the as-needed steroid-formoterol versus 0.20 with the reliever alone, a rate ratio of 0.36 (95% CI 0.27 to 0.49), while delivering only about 17% of the inhaled steroid dose of daily maintenance therapy. Measured in: 3,849 people aged 12 and over with mild asthma in a 52-week randomized double-blind trial. This is mild asthma, where whether a daily controller is even needed is a fair question; the as-needed steroid-formoterol matched the exacerbation protection of daily maintenance steroid while using far less steroid, but daily maintenance gave slightly better day-to-day symptom control. It is not a license to skip a prescribed daily controller in moderate or severe asthma.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the exacerbation rate separately by sex.
If you have mild asthma and rely on a reliever, ask whether a combined steroid-formoterol reliever is right for you. Even your as-needed inhaler can carry an anti-inflammatory, not just an opener.
The study · 1
O'Byrne et al., inhaled combined budesonide-formoterol as needed in mild asthma (SYGMA 1) · N Engl J Med 2018;378(20):1865-1876
Un soulageur stéroïdien à la demande a réduit d'environ moitié les crises quotidiennes en utilisation réelle
In a study designed to look like ordinary life, adults using a combined steroid-and-opener inhaler only when needed had about half the attacks of those using a plain blue reliever the same way. It backs up the tighter lab trials with real-world behavior.
L'essai ouvert Novel START a randomisé 668 adultes atteints d'asthme léger pour recevoir soit de l'albutérol à la demande (un soulageur bleu), soit du budésonide en entretien quotidien plus albutérol, soit du budésonide-formotérol à la demande, l'utilisation de l'inhalateur étant surveillée électroniquement pour refléter la pratique réelle. Le taux annuel d'exacerbations était de 0.195 avec le budésonide-formotérol contre 0.400 avec l'albutérol seul (taux relatif 0.49, IC à 95 % 0.33 à 0.72), et les exacerbations sévères se sont élevées à 9 contre 23 (risque relatif 0.40). Measured in: 668 adults with mild asthma in a 52-week open-label randomized controlled trial reflecting everyday practice. L'essai étant ouvert, les personnes savaient quel inhalateur elles utilisaient, ce qui peut influencer le comportement, bien que la surveillance électronique ait limité les incertitudes quant à l'observance. Il confirme, dans un contexte réel, ce que les essais en aveugle avaient montré, chez des adultes atteints d'asthme léger, non de maladie plus sévère.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the exacerbation rate separately by sex.
Le message pratique rejoint les essais en aveugle : un inhalateur à la demande contenant un stéroïde protège mieux qu'un soulageur bleu seul. Discutez du changement avec votre prescripteur, sans modifier vos inhalateurs de votre propre initiative.
The study · 1
Beasley et al., controlled trial of budesonide-formoterol as needed for mild asthma (Novel START) · N Engl J Med 2019;380(21):2020-2030
Dans l'asthme sévère à éosinophiles, un biologique a réduit les crises d'environ moitié (47 à 53 %)
Pour les personnes dont l'asthme sévère continue de s'aggraver malgré un traitement par inhalateur à forte dose, et qui présentent un taux élevé d'un type spécifique de cellule inflammatoire, un biologique injecté a réduit leurs crises d'environ moitié. Il s'adresse à ce groupe sévère spécifique, en complément des corticostéroïdes inhalés.
Dans l'essai MENSA, 576 personnes atteintes d'asthme sévère, d'exacerbations récurrentes et d'inflammation à éosinophiles malgré des corticostéroïdes inhalés à forte dose ont été randomisées pour recevoir du mépolizumab (un anticorps anti-interleukine-5) ou un placebo toutes les quatre semaines pendant 32 semaines. Les exacerbations ont diminué de 47 % avec le mépolizumab intraveineux et de 53 % avec le mépolizumab sous-cutané par rapport au placebo, avec une baisse supplémentaire des exacerbations nécessitant des soins d'urgence ou une hospitalisation, ainsi qu'une amélioration des scores de qualité de vie et de contrôle. Measured in: 576 people with severe eosinophilic asthma and recurrent exacerbations despite high-dose inhaled steroids, in a randomized double-blind trial. Cela concerne un sous-groupe spécifique, sévère et à éosinophiles, identifié par des analyses sanguines, non l'asthme en général, et le gain de fonction pulmonaire était modeste (environ 100 mL de VEMS). Les biologiques sont des traitements spécialisés, injectés, ajoutés aux corticostéroïdes inhalés, non un substitut à ceux-ci.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the exacerbation reduction separately by sex.
Si votre asthme reste sévère malgré une utilisation correcte d'inhalateurs à forte dose, demandez à un spécialiste de tester votre taux d'éosinophiles et si un biologique convient. Il s'ajoute à vos corticostéroïdes inhalés, il ne les remplace pas.
The study · 1
Ortega et al., mepolizumab treatment in patients with severe eosinophilic asthma (MENSA) · N Engl J Med 2014;371(13):1198-1207
La rééducation respiratoire a amélioré la qualité de vie de 0.42 sur l'AQLQ, mais pas la fonction pulmonaire
La rééducation respiratoire a amélioré la sensation d'asthme et la qualité de vie des personnes, mais n'a pas modifié la fonction pulmonaire ni l'inflammation des voies respiratoires. Elle aide à mieux vivre avec l'asthme ; elle ne traite pas la maladie, elle s'ajoute donc à un inhalateur de fond.
Une revue Cochrane portant sur 22 essais (2,880 participants) a montré que les exercices respiratoires amélioraient la qualité de vie liée à l'asthme sur l'AQLQ à trois mois (différence moyenne 0.42, IC à 95 % 0.17 à 0.68 ; preuves de certitude modérée) et soulageaient les symptômes d'hyperventilation, avec des effets non concluants sur la fonction pulmonaire. Le grand essai randomisé BREATHE (655 adultes) a confirmé un gain de qualité de vie par rapport aux soins habituels (différence moyenne ajustée 0.28), sans changement significatif du VEMS ni du monoxyde d'azote expiré. Measured in: Adults with mild to moderate asthma; 2,880 across 22 trials in the Cochrane review, and 655 with incompletely controlled asthma in the BREATHE trial. Le bénéfice porte sur la sensation d'asthme et les symptômes liés au schéma respiratoire, non sur la fonction pulmonaire ou l'inflammation des voies respiratoires, qui n'ont pas changé. C'est exactement pour cela qu'elle s'ajoute à un inhalateur de fond et ne peut le remplacer : elle ne traite pas la maladie sous-jacente.
Who this may not transfer to:Both sexes were enrolled across the pooled trials and the BREATHE trial; effects are not reported separately by sex.
La rééducation respiratoire mérite d'être essayée pour les symptômes et la qualité de vie, idéalement enseignée par un kinésithérapeute ou via un programme validé, tout en poursuivant votre inhalateur de fond. Ne l'utilisez pas comme prétexte pour réduire votre traitement.
The studies · 2
Santino et al., breathing exercises for adults with asthma · Cochrane Database Syst Rev 2020;3(3):CD001277
Bruton et al., physiotherapy breathing retraining for asthma (BREATHE), a randomised controlled trial · Lancet Respir Med 2018;6(1):19-28
Perdre 5 à 10 % du poids corporel a amélioré le contrôle de l'asthme chez 58 % et la qualité de vie chez 83 %
Chez les adultes en surpoids ou obèses souffrant d'asthme, une perte de 5 à 10 % du poids corporel a amélioré le contrôle de l'asthme chez la plupart des personnes et la qualité de vie chez la grande majorité. Elle agit sur la composante de l'asthme liée au poids et constitue un levier à utiliser si vous êtes en surpoids.
Un essai randomisé mené chez 46 adultes en surpoids ou obèses souffrant d'asthme a comparé 10 semaines de restriction alimentaire, d'exercice, ou des deux combinés. La perte de poids moyenne était de 8.5 % avec le régime et de 8.3 % avec le programme combiné. Une perte de 5 à 10 % du poids corporel a produit une amélioration cliniquement importante du contrôle de l'asthme chez 58 % des participants et de la qualité de vie chez 83 %, et les groupes régime et combiné ont amélioré significativement les scores de contrôle de l'asthme. Measured in: 46 overweight and obese adults with asthma (54% female, mean BMI 33.7) in a randomized trial of diet, exercise or both. L'essai était petit et de courte durée, et le bénéfice s'applique aux asthmatiques en surpoids ou obèses, non aux personnes de poids normal. La perte de poids agit sur la composante de l'asthme liée au poids ; elle complète le traitement par inhalateur, sans le remplacer.
Who this may not transfer to:Both sexes were enrolled (54% female); some inflammatory findings differed by sex, but the asthma-control benefit of weight loss was seen across the group.
Si vous êtes en surpoids et souffrez d'asthme, une perte de poids de 5 à 10 % est un objectif utile pouvant améliorer sensiblement le contrôle, en complément de vos inhalateurs habituels, non à leur place.
The study · 1
Scott et al., dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma, a randomized trial · Clin Exp Allergy 2013;43(1):36-49
Allergen immunotherapy eased allergic-asthma symptoms and cut medication, with about a one-in-nine reaction risk
Pour l'asthme provoqué par une allergie confirmée, l'immunothérapie administrée sur plusieurs années a réduit les symptômes et les médicaments nécessaires. Elle vise l'allergie elle-même, mais les injections comportent un faible risque de réaction allergique grave, elles sont donc réalisées là où celle-ci peut être traitée.
A Cochrane review of 88 trials of allergen-specific injection immunotherapy for asthma found a significant reduction in asthma symptoms (standardized mean difference -0.59, 95% CI -0.83 to -0.35) and in medication use, and improved bronchial hyper-reactivity. Roughly three people needed treatment to prevent one deterioration in symptoms. Around one in nine developed a systemic allergic reaction of some severity, so it carries a risk of anaphylaxis. Measured in: Adults and children with allergic asthma across 88 randomized controlled trials of allergen-specific immunotherapy. This treats asthma driven by a confirmed allergen and is a multi-year commitment, and injection immunotherapy carries a small risk of a severe allergic reaction, so it is given where staff can treat one. It reduced symptoms and medication without a consistent effect on lung function.
Who this may not transfer to:Both sexes and both children and adults were included across the pooled trials; effects are not reported separately by sex.
Immunotherapy is worth discussing when a specific allergy clearly drives your asthma and symptoms persist despite good inhaler treatment. It needs allergy testing first and a clinic set up to handle a reaction.
The study · 1
Abramson et al., injection allergen immunotherapy for asthma · Cochrane Database Syst Rev 2010;(8):CD001186
Smokers with asthma got no benefit from steroid tablets that lifted non-smokers' FEV1 237 mL
People with asthma who smoked got no benefit from a two-week course of steroid tablets, while non-smokers improved clearly. Ex-smokers responded partway, which suggests quitting brings some of the response back. Smoking undercuts the very treatment that controls asthma.
A randomized placebo-controlled crossover study gave two weeks of oral prednisolone to smokers, ex-smokers and never-smokers with asthma. Never-smokers improved significantly on prednisolone (FEV1 rose by a mean 237 mL, morning peak flow by 36.8 L/min, and asthma control scores improved), while active smokers showed no significant change on any measure. Ex-smokers fell in between, improving on peak flow but not FEV1 or control. Measured in: Adults with chronic stable asthma, grouped as smokers, ex-smokers and never-smokers, in a randomized placebo-controlled crossover trial. This tested short-term oral steroids, and the same steroid resistance is thought to extend to inhaled steroids in smokers, though this trial did not measure that. Smoking undermines the treatment that controls asthma, and stopping restores some of the response, as the ex-smoker results suggest.
Who this may not transfer to:Both sexes were enrolled; the trial does not report the steroid response separately by sex.
If you have asthma and smoke, stopping is one of the highest-value things you can do, since it restores how well your steroid inhaler and tablets work. Support to quit is worth asking for specifically on these grounds.
The study · 1
Chaudhuri et al., cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma · Am J Respir Crit Care Med 2003;168(11):1308-1311
Vitamin D did not reduce asthma attacks overall, with any benefit limited to severe deficiency
An early pooling of trials suggested vitamin D cut asthma attacks, especially in people who were very deficient. But adding newer trials in a 2023 review erased the average benefit. So it is a mixed picture, with any real effect likely limited to people who start out severely low in vitamin D.
An earlier individual-participant meta-analysis (955 people, seven trials) found vitamin D reduced the rate of exacerbations needing systemic steroids (adjusted incidence rate ratio 0.74, 95% CI 0.56 to 0.97), with the clearest benefit in people with very low baseline vitamin D. An updated 2023 Cochrane review of 20 trials (2,225 participants), including newer studies, found no reduction overall in the proportion having an exacerbation (odds ratio 1.04, 95% CI 0.81 to 1.34). Profound vitamin D deficiency was rare in these trials. Measured in: Children and adults with mostly mild to moderate asthma across up to 20 randomized placebo-controlled trials. The picture is mixed: the early signal appeared, but adding later trials washed out the average benefit, and any effect looks confined to people who start out severely deficient, not the general asthma population. Correcting a true deficiency is reasonable on its own terms; vitamin D is not a reliable way to prevent attacks in people who are already replete.
Who this may not transfer to:Both sexes and both children and adults were included; the pooled analyzes do not show a consistent difference by sex.
If a blood test shows you are clearly deficient, correcting that is worthwhile in itself. Do not rely on vitamin D as an asthma treatment or as a reason to ease off your inhalers.
The studies · 2
Jolliffe et al., vitamin D supplementation to prevent asthma exacerbations, a systematic review and meta-analysis of individual participant data · Lancet Respir Med 2017;5(11):881-890
Williamson et al., vitamin D for the management of asthma · Cochrane Database Syst Rev 2023;2(2):CD011511
Acupuncture did not improve lung function in asthma versus sham
Across small trials, acupuncture did not improve lung function in asthma compared with a fake-needle procedure. The studies were weak, so it is not a firm verdict, but there is no good evidence it improves the breathing measures, and it does not replace a controller inhaler.
A Cochrane review of 11 trials (324 participants) of acupuncture for asthma found no statistically significant or clinically relevant effect compared with sham acupuncture. Pooled lung-function data from two trials gave a standardized mean difference of 0.12 (95% CI -0.31 to 0.55) for post-treatment FEV1. Trial quality was low and the types of acupuncture and outcomes varied widely. Measured in: 324 people with asthma across 11 randomized or possibly randomized trials of acupuncture. The trials were small and poorly reported, so this is a weak evidence base, not a firm verdict, and some studies used points on the sham arm that traditional Chinese medicine also uses for asthma, blurring the comparison. On what exists, acupuncture has not been shown to improve lung function, so it does not substitute for controller treatment.
Who this may not transfer to:Both sexes were included across the small trials; effects are not reported separately by sex.
If you find acupuncture helpful for wellbeing, there is no reason to avoid it, but do not use it in place of your asthma inhalers or expect it to improve your lung function.
The study · 1
McCarney et al., acupuncture for chronic asthma · Cochrane Database Syst Rev 2004;(1):CD000008
Cardiorespiratory Fitness
L'exercice régulier a augmenté la condition physique de 4.92 mL/kg/min sans aggraver l'asthme
L'exercice régulier a rendu les personnes asthmatiques nettement plus en forme et n'a pas aggravé leur asthme. Il améliore la condition physique et le bien-être, non l'asthme lui-même ; le message est donc de rester actif une fois l'asthme maîtrisé, non d'éviter l'exercice.
Une revue Cochrane portant sur 21 essais (772 personnes âgées de 8 ans et plus) a montré que l'entraînement physique augmentait la consommation maximale d'oxygène de 4.92 mL/kg/min (IC à 95 % 3.98 à 5.87), un gain de condition physique cliniquement significatif, avec des signes d'amélioration de la qualité de vie. L'entraînement était bien toléré, aucune étude n'a rapporté d'aggravation de l'asthme, et les mesures de fonction pulmonaire telles que le VEMS n'ont pas changé. Measured in: 772 people aged 8 and over with asthma across 21 randomized trials of physical training. L'exercice améliore la condition physique et le bien-être, non l'asthme lui-même, et doit être entrepris sur une base contrôlée, car l'exercice peut déclencher des symptômes en cas d'asthme mal maîtrisé. Les essais ont porté sur des personnes dont l'asthme était suffisamment stable pour s'entraîner.
Who this may not transfer to:Both sexes were enrolled across the pooled trials; effects are not reported separately by sex.
Si votre asthme est maîtrisé, intégrez une activité régulière, et utilisez un soulageur ou une dose préalable à l'exercice si celui-ci déclenche des symptômes. Si l'exercice déclenche systématiquement des symptômes importants, c'est le signe que l'asthme sous-jacent doit d'abord être mieux maîtrisé.
The study · 1
Carson et al., physical training for asthma · Cochrane Database Syst Rev 2013;(9):CD001116
Where the evidence does not hold up
Vitamin D looked promising in an early pooling of trials, especially for people who were very deficient. Adding newer studies in a 2023 Cochrane review washed out the average benefit. The picture is mixed, so it is not a reliable way to prevent attacks in someone whose vitamin D is already normal. Correcting a confirmed deficiency is reasonable on its own terms.
Acupuncture, across 11 small trials, did not improve lung function compared with a sham needle procedure. The trials were weak, so the evidence is only suggestive. If you find it steadies you, there is no reason to avoid it.
Getting Asthma Under Control
This is how to get the most from the plan your prescriber has you on. Take the controller every day, treat a fast-emptying reliever as a signal to get reviewed, and reduce the things that set the airways off.
The controller calms the inflammation over days and weeks, so it only works if taken daily, including on the days you feel fine. Its job is to prevent the next flare, which is why it continues when nothing feels wrong.
Have a pharmacist or nurse watch you use the inhaler once, and add a spacer where it helps. Most of the lost dose is technique, so getting more of it to the airway makes a real difference.
A reliever canister emptying fast is a sign the asthma is not controlled. Treat it as the trigger to get your treatment reviewed, so the underlying inflammation gets addressed.
A written plan sets out your daily treatment, what to do as symptoms build, and when to seek urgent help. On paper, it gives you clear steps to follow on a bad day instead of guesswork.
Reduce the exposures that set your airways off, and keep any hay fever treated. Of everything here, stopping smoking is the single highest-value move.
Exercise builds fitness and does not worsen well-controlled asthma, and losing weight if you carry extra improves control. Both add to what your inhalers do.
Go Deeper
- Breathing retraining: the breathing technique studied in asthma, and the symptoms it helps.
- Walking and exercise: why staying active builds fitness without worsening controlled asthma, and how to start.
- Whole foods: the eating shift behind the weight loss that improves control in overweight adults.
- Pranayama: the yogic breathing exercises studied in asthma, what they ease, and what they do not change.
The Chinese Medicine View
The Chinese Medicine View
Chinese medicine reads asthma as Xiao Zheng (哮症), wheezing with an audible sound, and Chuan Zheng (喘症), labored panting breath, the two often named together as Xiao Chuan. The central idea is a hidden store of Phlegm in the Lung. A trigger (cold air, an allergen, exertion, or emotion) stirs it into an attack. During an attack the tradition treats the branch, opening the Lung and moving Phlegm. Between attacks it treats the root, strengthening the organs that let Phlegm gather. A practitioner reads an acute attack as a Cold or a Hot pattern. Recurrent asthma is traced to deficiency of the Lung, Spleen, or Kidney.
An acute attack brought on by cold: wheezing with a tight chest, thin white or foamy sputum, no thirst, worse in cold air or winter. The Phlegm is read as cold and watery. The classical direction is to warm the Lung, scatter Cold and transform Phlegm, the picture She Gan Ma Huang Tang is built for.
An acute attack running hot: loud wheezing, a full chest, thick yellow sputum that is hard to bring up, thirst, a flushed face, worse in heat. The direction is to clear Heat, transform Phlegm and calm the wheezing, the picture of a formula such as Ding Chuan Tang.
The chronic root in many people: breathlessness on exertion, a weak voice, sweating easily, catching every cold, poor appetite, loose stools and tiredness. The Spleen is seen as producing the Phlegm that the Lung then stores. The direction is to strengthen the Lung and Spleen and stop Phlegm forming.
Long-standing asthma where the breath cannot settle: shortness of breath worse on exertion and on breathing in, cold limbs, weak lower back and knees, worse in winter. The Kidney is seen as failing to grasp the Qi and hold the breath down. The direction is to warm and tonify the Kidney so it can anchor the breathing.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
A short steroid-tablet course after an attack cut relapse in the first week (relative risk 0.38)
A Cochrane review of six trials (374 people) found that a short course of corticosteroids given after treatment for an acute asthma attack cut the chance of relapsing and needing more care in the first week (relative risk 0.38, 95% CI 0.20 to 0.74), an effect maintained over 21 days, with fewer subsequent hospitalizations (relative risk 0.35) and less need for the reliever, and no clear rise in side effects. As few as ten people needed treating to prevent one relapse. This is a short rescue course to recover from a flare, not a long-term treatment, since prolonged oral steroids carry their own risks. Starting it early in a bad attack is what the evidence supports, which is one reason a severe attack needs prompt medical assessment.Rowe et al., corticosteroids for preventing relapse following acute exacerbations of asthma
Une utilisation importante du soulageur bleu était associée à jusqu'à 77 % de crises en plus et à un risque de décès plus élevé
La cohorte nationale SABINA a relié des registres suédois pour 365,324 patients asthmatiques âgés de 12 à 45 ans, suivis en moyenne pendant environ sept ans. La surconsommation du soulageur à action rapide, définie comme plus de deux flacons par an, était fréquente (30 % des patients) et augmentait avec le risque. Par rapport à deux flacons ou moins par an, en obtenir 3 à 5 était associé à un risque d'exacerbation supérieur de 26 %, 6 à 10 à un risque supérieur de 44 %, et 11 ou plus à un risque supérieur de 77 % ; pour la mortalité, les rapports de risque étaient respectivement de 1.26, 1.67 et 2.35 (2,564 décès observés). Il s'agit d'une association observationnelle, qui n'établit donc pas que le soulageur lui-même cause ce préjudice ; la quantité consommée par une personne est en partie un marqueur de la gravité et du mauvais contrôle déjà présents de son asthme. Quoi qu'il en soit, un flacon qui s'épuise rapidement est un signal fiable indiquant que l'asthme doit être réévalué, et non qu'il faut davantage de soulageur.Nwaru et al., overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality, the global SABINA programme
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
When to See Someone
One rule matters most: a controller inhaler is not something to stop or cut back on your own. Stopping it lets airway inflammation return, often before symptoms do. These are the signs to act on, and the first is an emergency:
- A severe attack: too breathless to speak a full sentence, walk, or lie flat; the reliever not working or wearing off within an hour; lips or fingertips turning blue or gray; exhaustion or drowsiness; or a chest that has gone quiet with no wheeze left. Call emergency services and keep taking the reliever while you wait(seek urgent care)
- Needing the reliever more than about twice a week, or waking at night with asthma. Either means it is not controlled, so get the treatment reviewed
- A peak flow reading that is dropping, or falling well below your personal best, especially alongside more symptoms, which can warn of a flare building before you feel it
- Symptoms getting steadily worse over several days despite normal inhaler use. Get seen
- A new or worsening wheeze, cough, or breathlessness in someone with hay fever or eczema: get the chest assessed
- First-ever wheeze and breathlessness in an adult. Or breathlessness with chest pain, a racing heartbeat, or swollen legs, these can be something other than asthma and need diagnosis(seek urgent care)
Use these signs to tell an ordinary symptom day from an attack, and keep the controller going in between.
Common Questions
Do I really need the controller inhaler if I feel fine?
Yes. The controller settles airway inflammation slowly, so its protection builds over daily use and fades once you stop. Quit because symptoms went quiet and the inflammation returns, often before you feel it again.
What is the difference between the blue and the brown inhaler?
They do different jobs. The blue reliever widens the airway for a few hours to ease a flare, and leaves the inflammation behind. The brown or colored controller settles that inflammation over time, so it is the one that changes how the illness behaves. The newer twist is that an as-needed inhaler can itself carry a low-dose steroid.
Is it safe to exercise with asthma?
Once the asthma is controlled, exercise is good for it. If exercise reliably brings on a wheeze, warm up first and use a reliever or pre-exercise dose as your clinician advises. Treat that wheeze as a signal the asthma itself needs firmer control, and keep moving.
Do natural remedies work for asthma?
Some ease how asthma feels without changing what is happening in the airway. Breathing retraining is the clearest example of that split. Weigh each one by the graded findings and by whether it steadies you.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 15 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.